Skip to main content
construction release_alert
Profile editing is temporarily unavailable from June 11-24, 2026 while manual profile data entry transitions to Elements. Learn More.
cancel

Yuan Wu

Associate Professor in Biostatistics & Bioinformatics
Biostatistics & Bioinformatics, Division of Biostatistics
Duke Box 2721, Durham, NC 27710
2424 Erwin Road, 11101 Hock Plaza Suite 1102, Durham, NC 27710

Overview


Survival analysis, Sequential clinical trial design, Machine learning, Causal inference, Non/Semi-parametric method, Statistical computing

Current Appointments & Affiliations


Associate Professor in Biostatistics & Bioinformatics · 2022 - Present Biostatistics & Bioinformatics, Division of Biostatistics, Biostatistics & Bioinformatics
Member of the Duke Cancer Institute · 2021 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


Residual-Based Sieve Maximum Full Likelihood Estimation for the Proportional Hazards Model.

Journal Article Commun Stat Theory Methods · May 16, 2026 The partial likelihood approach is the gold standard approach for estimating regression parameters in proportional hazards model, largely because it avoids specifying the baseline hazard function. However, this approach can lack robustness in the presence ... Full text Link to item Cite

Win Ratio as an Effect Size Measure Under Non-Proportional Hazards: A Comparison With Difference in Restricted Mean Survival.

Journal Article Stat Med · May 2026 When the proportional hazards assumption does not hold, the hazard ratio can misrepresent treatment effects in survival analysis. We evaluate the win ratio, originally proposed for prioritizing multiple outcomes, as an effect size measure for a single surv ... Full text Link to item Cite

Real-world early quality of life (QOL) changes on IO-based regimens in the prospective observational ODYSSEY metastatic renal cell carcinoma (mRCC) study.

Conference Journal of Clinical Oncology · March 1, 2026 Lack of standardized reporting and collection of patient-reported outcomes (PROs) limits cross-trial comparisons of first-line IO-based regimens for mRCC. Prospectively collected real world data may fill this important knowledge gap. Pts with stable/improv ... Full text Cite
View All Publications

Recent Grants


Assessment of the Optimal Settings of TFL for Laser Lithotripsy and Associated Thermal Injury Risk

ResearchCo Investigator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2025 - 2028

Kidney Cancer Research Program Clinical Consortium Duke University Clinical Trial Site Award

ResearchBiostatistician · Awarded by Department of Defense · 2024 - 2028

View All Grants

Education


University of Iowa · 2010 Ph.D.